

The antiphospholipid syndrome in patients with system

Journal of Autoimmunity

76, 10-20

DOI: [10.1016/j.jaut.2016.10.004](https://doi.org/10.1016/j.jaut.2016.10.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Utility of thrombophilia testing in patients with venous thrombo-embolism. <i>Journal of Thoracic Disease</i> , 2016, 8, 3697-3703.	1.4	11
2	The evolving concept of SLE comorbidities. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 753-768.	3.0	30
3	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1823-1831.	5.6	70
4	Autoimmunity in 2016. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 126-139.	6.5	9
5	Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e7-e8.	3.4	13
6	Depressed serum IgM levels in SLE are restricted to defined subgroups. <i>Clinical Immunology</i> , 2017, 183, 304-315.	3.2	22
7	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000225.	2.7	18
8	Livedo Reticularis on the Lower Limbs in a Patient with Lupus Erythematosus: A Quiz. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1148-1149.	1.3	0
9	Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1350-1357.	1.9	28
11	Systemic and Biologic Agents for Lupus Erythematosus. , 2018, , 377-390.		0
12	Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study. <i>Lupus</i> , 2018, 27, 556-563.	1.6	8
13	Antiphospholipid Antibody Positivity and the Clinical Outcomes of Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 239.	1.1	3
14	Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2644.	4.8	16
15	Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2018, 25, 16-21.	0.0	0
17	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	2.6	16
18	Antiphospholipid Syndrome and Thrombocytopenia. , 2018, , .		2
19	Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2018, 93, 16-23.	6.5	35
20	Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. <i>Journal of Rheumatology</i> , 2018, 45, 1263-1272.	2.0	24

#	ARTICLE	IF	CITATIONS
21	Clinical implications of systemic lupus erythematosus without and with antiphospholipid syndrome in peri- and postmenopausal age. <i>Przegląd Menopauzalny</i> , 2018, 17, 86-90.	1.3	4
22	Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. <i>BMC Pregnancy and Childbirth</i> , 2018, 18, 212.	2.4	15
23	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. <i>Autoimmunity Reviews</i> , 2018, 17, 739-745.	5.8	26
24	Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 59, 534-544.	1.9	3
25	Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 167.	1.7	1
26	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 468-477.	2.7	19
27	Neutrophilsâ€™ Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 2734.	4.8	49
28	Metabolic syndrome and systemic lupus erythematosus: the connection. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 765-775.	3.0	34
29	Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2019, 8, 796.	2.4	31
30	The Contribution of Drugs and <i>Helicobacter pylori</i> to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>International Journal of Rheumatology</i> , 2019, 2019, 1-18.	1.6	6
31	Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies. <i>Rheumatology International</i> , 2019, 39, 1359-1367.	3.0	4
32	Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL). <i>Frontiers in Immunology</i> , 2019, 10, 885.	4.8	20
33	Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form. <i>Frontiers in Immunology</i> , 2019, 10, 941.	4.8	68
34	The efficacy and safety of antithrombotic therapy in patients with positive antiphospholipid antibodies receiving invasive procedures: experience from a single tertiary center. <i>Clinical Rheumatology</i> , 2019, 38, 1897-1904.	2.2	4
35	Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1597-1605.	1.7	5
36	Acute papillary muscle infarction and rupture in the puerperium complicating Libmanâ€™Sacks endocarditis in a patient with systemic lupus erythematosus and antiphospholipid syndrome: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-4.	0.6	3
37	Hemoptysis and a cardiac murmur: is it primary or secondary antiphospholipid syndrome?. <i>Lupus</i> , 2019, 28, 1712-1715.	1.6	4
38	Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. <i>Rheumatology</i> , 2019, 58, 1006-1010.	1.9	15

#	ARTICLE	IF	CITATIONS
39	Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment. <i>Autoimmunity Reviews</i> , 2019, 18, 312-314.	5.8	19
40	Clinical profiles and risk assessment in patients with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 73-81.	3.0	10
41	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	3.4	37
42	The Perioperative Medicine Consult Handbook. , 2020, , .		0
43	Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 5-22.	3.0	3
44	Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. <i>Autoimmunity</i> , 2020, 53, 21-27.	2.6	10
45	Renal involvement in systemic lupus erythematosus: additional histopathological lesions. <i>Archives of Medical Science</i> , 2020, , .	0.9	1
46	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. <i>Rheumatology</i> , 2020, 59, v29-v38.	1.9	80
47	Clinical manifestations and maternal and perinatal outcomes in pregnant women with obstetric antiphospholipid syndrome at a high complexity institution: Descriptive study. <i>Revista Colombiana De ReumatologAa (English Edition)</i> , 2020, 27, 73-79.	0.0	0
48	Systemic Lupus Erythematosus: Considerations in Diagnosis and Management for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2020, 9, 220-230.	2.1	0
49	â€œNon-criteriaâ€•antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	5.8	37
50	Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment. <i>Clinical Rheumatology</i> , 2020, 39, 3365-3371.	2.2	5
51	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020, 22, 67.	4.7	31
52	A 75â€•yearâ€•old woman with primary antiphospholipid syndrome presenting with livedoid vasculopathy. <i>Dermatologic Therapy</i> , 2020, 33, e13480.	1.7	0
53	Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study. <i>Journal of Korean Medical Science</i> , 2020, 35, e35.	2.5	33
54	Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>World Neurosurgery</i> , 2020, 136, 248-252.	1.3	5
55	Visualization and analysis of the interaction network of proteins associated with blood-cell targeting autoimmune diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165714.	3.8	3
56	Acute Myocardial Infarction in Autoimmune Rheumatologic Disease: A Nationwide Analysis of Clinical Outcomes and Predictors of Management Strategy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 388-399.	3.0	10

#	ARTICLE	IF	CITATIONS
57	Precision medicine in autoimmune disease. , 2021, , 169-187.		0
58	SARS-CoV-2 and Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2021, 23, 8.	4.7	18
59	Neurologic Manifestations of Systemic Disease: Movement Disorders. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	1.8	0
60	Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets. <i>Science China Life Sciences</i> , 2021, 64, 1702-1719.	4.9	13
61	Longitudinal Analysis of Anti-cardiolipin and Anti-Î²2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. <i>Frontiers in Medicine</i> , 2021, 8, 646846.	2.6	4
62	Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers. <i>Lupus</i> , 2021, 30, 828-832.	1.6	6
63	Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis. <i>Lupus</i> , 2021, 30, 1140-1145.	1.6	3
64	miR-19b-3p and miR-20a-5p are associated with the levels of antiphospholipid antibodies in patients with antiphospholipid syndrome. <i>Rheumatology International</i> , 2021, 41, 1329-1335.	3.0	7
65	Low Intra-Individual Variation in Mean Platelet Volume Over Time in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 638750.	2.6	4
66	Anti-beta 2 glycoprotein 1 domain IgA positive antiphospholipid syndrome secondary to incomplete Behcetâ€™s disease: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 7114-7120.	1.2	1
67	Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2728.	2.4	9
68	Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 52-60.	7.2	36
69	Coexistence of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren Syndrome, Antiphospholipid Syndrome, and Ankylosing Spondylitis. <i>Case Reports in Rheumatology</i> , 2021, 2021, 1-5.	0.6	1
70	Treat-to-target in systemic lupus erythematosus: Where are we?. <i>European Journal of Internal Medicine</i> , 2020, 74, 29-34.	2.2	19
71	Antiphospholipid syndrome and pregnancy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 277-285.	0.8	4
72	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 7-15.	0.8	33
73	Anesthesia for the Pregnant Patient with Autoimmune Disorders. , 2018, , 87-97.		0
74	DEMONSTRATION OF THE IMMUNE AND AUTOIMMUNE COMPONENTS OF INFLAMMATION IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS AND ISCHEMIC HEART DISEASE. Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2019, 17, 445-452.	0.1	0

#	ARTICLE	IF	CITATIONS
75	Kidney damage associated with anti-phospholipid syndrome. <i>PoĀki</i> , 2019, 8, 161-173.	0.4	4
77	Cardiovascular manifestations in patients with antiphospholipid syndrome: issues of diagnosis and management. <i>Hypertension</i> , 2019, .	0.2	0
79	Antiphospholipid Syndrome: Nephrologistsâ€™ Perspective. <i>Open Journal of Internal Medicine</i> , 2020, 10, 112-120.	0.2	0
80	Tongue Stiffness as Presentation of Antiphospholipid Syndrome: A Case Report. <i>Cureus</i> , 2020, 12, e8584.	0.5	0
81	An unusual case of antiphospholipid syndrome in a young man detected by cardiac magnetic resonance. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 503-505.	1.5	0
82	Thrombotic risk assessment in patients with systemic lupus erythematosus: Validation of the adjustedâ€”Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1510-1519.	1.9	2
83	Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.6	0
84	Manifestaciones clĀnicas y desenlaces maternos y perinatales en gestantes con sĀndrome antifosfolĀpido obstĀtrico de una instituciĀn de alta complejidad: estudio descriptivo. <i>Revista Colombiana De ReumatologĀa</i> , 2020, 27, 73-79.	0.1	0
85	Effects of antiâ€”beta 2â€”glycoprotein 1 antibodies and its association with pregnancyâ€”related morbidity in antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2022, 87, e13509.	1.2	9
86	Portal vein thrombosis â€” a literature review and our own clinical observations. <i>EkspĀrimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, , 55-62.	0.4	0
87	Pregnancy Management in Women with Antiphospholipid Syndrome. <i>MĀdica</i> , 2019, 14, 148-160.	0.1	2
88	Idiopathic Normal Pressure Hydrocephalus - What We Know. <i>MĀdica</i> , 2019, 14, 161-164.	0.1	1
89	A retrospective review of antiphospholipid syndrome from a South Asian country. <i>Archives of Rheumatology</i> , 0, , .	0.9	1
90	Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index. <i>Archives of Rheumatology</i> , 2022, 37, 252-260.	0.9	2
91	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. <i>Seminars in Immunopathology</i> , 2022, 44, 347-362.	6.1	67
92	Non-ST-elevation myocardial infarction hiding behind myopericarditis in a patient with systemic lupus erythematosus. <i>BMJ Case Reports</i> , 2022, 15, e243540.	0.5	0
98	The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210885.	1.7	19
101	Neurological complications in systemic inflammatory diseases. <i>Current Rheumatology Reviews</i> , 2022, 18, .	0.8	0

#	ARTICLE	IF	CITATIONS
102	mir-146a genetic polymorphisms in systemic lupus erythematosus patients: Correlation with disease manifestations. <i>Non-coding RNA Research</i> , 2022, 7, 142-149.	4.6	4
103	Improved pregnancy outcomes in systemic lupus erythematosus: A retrospective study of pregnancies from a single centre in Denmark from 2010–2020 compared with the period 1990–2010. <i>Lupus</i> , 0, , 096120332211075.	1.6	2
104	Predictors and prognostic stratification for lupus low disease activity state: results from a prospective clinical trial. <i>Rheumatology</i> , 2023, 62, 1153-1161.	1.9	0
105	Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus. <i>Cmaj</i> , 2022, 194, E1243-E1247.	2.0	2
106	The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. <i>Thrombosis Journal</i> , 2022, 20, .	2.1	4
107	A decreased number of circulating regulatory T cells is associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	2.7	4
108	Lupus nephritis: Is it necessary to systematically repeat kidney biopsy?. <i>Revue De Medecine Interne</i> , 2023, 44, 1-4.	1.0	1
109	The complement system and human autoimmune diseases. <i>Journal of Autoimmunity</i> , 2023, 137, 102979.	6.5	26
110	Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
111	Complications thrombotiques graves du syndrome des antiphospholipides et d'un lupus érythémateux disséminé non diagnostiqué. <i>Cmaj</i> , 2023, 195, E43-E48.	2.0	0
112	COVID-19 in patients with Systemic Lupus Erythematosus and the antiphospholipid syndrome. , 2023, , 529-555.		0
113	Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts. <i>Journal of Clinical Medicine</i> , 2023, 12, 891.	2.4	3
114	Interaction between Long Noncoding RNAs and Syncytin-1/Syncytin-2 Genes and Transcripts: How Noncoding RNAs May Affect Pregnancy in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2259.	4.1	1
115	Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3195.	4.1	5
116	Acrocyanosis and retiform purpura as the first manifestation of catastrophic antiphospholipid syndrome in a child: A case report. <i>Dermatologica Sinica</i> , 2023, 41, 54.	0.5	0
117	Wolf Bite. , 2023, , 535-543.		0
118	Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study. <i>RMD Open</i> , 2023, 9, e002881.	3.8	3
119	An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 617.	4.0	1

#	ARTICLE	IF	CITATIONS
120	Correlation of some Immunological Markers with Systemic Lupus Erythematosus disease. , 2020, 12, 50-68.		0
121	Reduced circulating Tregs and positive pANCA were robustly associated with the occurrence of antiphospholipid syndrome in patients with systemic lupus erythematosus. Lupus, 2023, 32, 746-755.	1.6	0
122	A rare simultaneous presentation of combined occlusion and optic neuritis in a lupus erythematosus patient with anti-phospholipid antibody syndrome. Lupus, 2023, 32, 804-809.	1.6	1
123	Persistent Foramen Ovale Associated with Systemic Lupus as a Cause of Acute Ischemic Stroke - A Case Report. , 2023, .		0
124	Platelets and the Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus or Antiphospholipid Syndrome. TH Open, 2023, 07, e155-e167.	1.4	2
125	Positive antiphospholipid antibodies: observation or treatment?. Journal of Thrombosis and Thrombolysis, 2023, 56, 301-314.	2.1	2
126	Modulation of the activation of endothelial nitric oxide synthase and nitrosative stress biomarkers by aspirin triggered lipoxins: A possible mechanism of action of aspirin in the antiphospholipid syndrome. American Journal of Reproductive Immunology, 2023, 90, .	1.2	0
127	Polyautoimmunity in patients with cutaneous lupus erythematosus: a nationwide sex- and age-matched cohort study from Denmark. JAAD International, 2023, , .	2.2	0
128	Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren's syndrome: a retrospective cohort study. RMD Open, 2023, 9, e003439.	3.8	1
129	Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open, 2023, 9, e003302.	3.8	0
130	Trophoblast Cell Function in the Antiphospholipid Syndrome. Biomedicines, 2023, 11, 2681.	3.2	1
131	The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome. Rheumatology International, 0, , .	3.0	0
132	Pediatric antiphospholipid syndrome. Medicinski Podmladak, 2023, 74, 49-55.	0.0	0
133	Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Research and Therapy, 2023, 25, .	3.5	7
134	Risk of venous thromboembolism in autoimmune diseases: A comprehensive review. Autoimmunity Reviews, 2023, 22, 103447.	5.8	1
136	Antiphospholipid Antibody Testing: An Audit on Testing Practices in a Public Tertiary Care Center. Journal of Clinical Medicine, 2024, 13, 243.	2.4	0
137	Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the <scp>COMOSLEâ€EGYPT</scp> study. International Journal of Rheumatic Diseases, 2024, 27, .	1.9	0
138	Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: A narrative review with emphasis on efficacy and safety. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2024, 294, 148-155.	1.1	0

#	ARTICLE	IF	CITATIONS
140	Systemic lupus erythematosus and antiphospholipid syndrome complicating infratentorial subdural hematoma: A case report. <i>Asian Journal of Surgery</i> , 2024, 47, 1869-1870.	0.4	0
141	<i><i>Not So Benign</i> Antiphospholipid Antibody Syndrome: Clots, Complement, and Catastrophe!.</i> , 2024, 21, .		0
142	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. <i>Rheumatology</i> , 2024, 63, SI72-SI85.	1.9	1
143	Significance of determination of lipoprotein-associated Phospholipase A2 in patients with antiphospholipid syndrome. <i>Medicinski Podmladak</i> , 2023, 74, 69-74.	0.0	0
144	Rare diagnosis of coexistent antiphospholipid syndrome and systemic lupus erythematosus in a male patient with successful management: a case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 1983-1986.	1.1	0
145	Prevalence of concomitant rheumatologic diseases and autoantibody specificities among racial and ethnic groups in SLE patients. , 0, 4, .		0
146	Chorea as an initial and solitary manifestation of systemic lupus erythematosus with antiphospholipid syndrome in an elderly man. <i>BMJ Case Reports</i> , 2024, 17, e257086.	0.5	0